Exit stage left for senior leaders at Intrexon

Intrexon ($XON) has announced the departure of its chief operating officer, Krish Krishnan, and SVP of product development Suma Krishnan, effective immediately. The Virginia-based company, which focuses on synthetic biology, said in a statement this was because of the "successful growth of the company"--and also because it has hired new senior members to run the five business sectors across the company. The two roles will now be spread among a number of existing officers, with Joel Liffmann, SVP of finance, taking on primary responsibility for operating divisions. Randal Kirk, chairman and CEO of Intrexon, said: "I would like to thank Krish and Suma for their contributions to the company." Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.